Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 2:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorder Clear all

Conditions: Osteoarthritis of the Knee
Interventions: Lorecivivint; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 4
States / cities: Tucson, Arizona • Winter Park, Florida • Oak Brook, Illinois + 1 more

Conditions: Hyperphosphatemia, End-stage Renal Disease
Interventions: ferric citrate; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 19 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Short Stature
Interventions: Growth Hormone; Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 5 Years to 11 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions: AAV2-hAADC; Drug
Lead sponsor: Russell Lonser; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Hematologic Diseases, Anaemia, Sickle Cell
Interventions: GSK4172239D, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Miami, Florida • Tamarac, Florida • Atlanta, Georgia + 3 more

Conditions: Leukemia
Interventions: No Intervention; Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,769 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
Interventions: nilotinib; Drug
Lead sponsor: Andrew J. Wagner, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 7
States / cities: Santa Monica, California • Stanford, California • Tampa, Florida + 3 more

Conditions: Colorectal Neoplasms
Interventions: Vicriviroc, Pembrolizumab; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 6
States / cities: Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more

Conditions: Pulmonary Emphysema
Interventions: Treatment plus Optimal Medical Therapy, Optimal Medical Therapy; Device · Other
Lead sponsor: Aeris Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Papillomavirus Infections
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 25 Years to 65 Years · Female only
Enrollment: 503 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Solid Tumor, Triple Negative Breast Cancer
Interventions: RX-5902; Drug
Lead sponsor: Rexahn Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 8
States / cities: Tucson, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more

Conditions: Obesity
Interventions: CP-866,087, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Orlando, Florida • Kalamazoo, Michigan • Portland, Oregon + 1 more

Conditions: Portopulmonary Hypertension, Pulmonary Hypertension, Cirrhosis, Liver
Interventions: Ambrisentan Pill, Tadalafil Pill; Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: HIV Infection, HIV Infections
Interventions: Adherence report; Behavioral
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Primary Myelofibrosis, Secondary Myelofibrosis
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Melphalan, Methotrexate, Mycophenolate Mofetil, Ruxolitinib, Tacrolimus, Total-Body Irradiation, Computed Tomography, Echocardiography, Bone Marrow Aspiration and Biopsy, Magnetic Resonance Imaging, Ultrasound Imaging; Procedure · Drug · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: End Stage Renal Disease
Interventions: the SPIRIT intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Myelodysplastic Syndromes
Interventions: Clofarabine; Drug
Lead sponsor: Texas Oncology Cancer Center; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Amarillo, Texas

Conditions: Suspected CSF Shunt Obstruction
Interventions: ShuntCheck-Micro-Pumper (SCMP), Imaging; Device
Lead sponsor: NeuroDx Development; Industry
Eligibility: 35 Months to 29 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 11
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Chicago, Illinois + 8 more

Conditions: Gingivitis, Plaque
Interventions: Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush, 5% Hydroalcohol Mouthrinse, Mouthrinse Prototype 1, Mouthrinse Prototype 2; Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: LDX 30 mg, LDX 50 mg, LDX 70 mg, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 45
States / cities: Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 40 more

Conditions: Dementia
Interventions: Group-Based Digital Gaming; Behavioral
Lead sponsor: George Mason University; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Asthma
Interventions: FS MDPI, Fp MDPI, Placebo MDPI, albuterol/salbutamol, Beclomethasone dipropionate; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 76
States / cities: Birmingham, Alabama • Glendale, Arizona • Cypress, California + 64 more

Conditions: Atopic Dermatitis
Interventions: Skin tape strips; Other
Lead sponsor: National Jewish Health; Other
Eligibility: 4 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: BK Virus Infection
Interventions: Viralym-B; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Search by objective public record fields.

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature

AAV2-hAADC for Parkinson's Disease (PDCS-01)

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE)

HPV Infections in Older Women

RX-5902 Treatment of Subjects With Triple Negative Breast Cancer

Study To Determine The Effects And Safety Of A Weight Loss Compound On Overweight, Otherwise Healthy, Volunteers

Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension

Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

A Representational Intervention to Promote Preparation for End-of-life Decision Making

Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)

ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study

Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque

Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Group Digital Gaming: Experiences of Older Adults Living With Dementia in an Activity for Cognitive Impairment

Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma

Skin Tape Transcriptome Methods in Children

Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)